{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-23-000199","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2023-11-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.767593+00:00","generated_at":"2026-06-07T20:55:45.421294+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Emergent BioSolutions gets $75M BARDA contract option for CYFENDUS anthrax vaccine","bullets":["BARDA exercised a $75 million option under contract HHSO100201600030C for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted).","Deliveries begin in 2023 and are expected to be complete by end of Q1 2024.","CYFENDUS was approved by FDA in July 2023 as a two-dose post-exposure prophylaxis for ages 18+.","The vaccine supports U.S. anthrax preparedness strategy and is part of Emergent's medical countermeasures franchise."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-23-000199","json":"https://secwatch.observer/filing/0001367644-23-000199.json","markdown":"https://secwatch.observer/filing/0001367644-23-000199.md","text":"https://secwatch.observer/filing/0001367644-23-000199.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000199/0001367644-23-000199-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000199/ebs-20231121.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T20:55:45.421294+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}